Home
Resources
Publications
Bretylium Tosylate as Initial Treatment for Cardiopulmonary Arrest: Randomized Comparison With Placebo

Bretylium Tosylate as Initial Treatment for Cardiopulmonary Arrest: Randomized Comparison With Placebo

R M Nowak, T J Bodnar, S Dronen, G Gentzkow, M C Tomlanovich

Ann Emerg Med. 1981 Aug;10(8):404-7.

PMID: 7258754

Abstract:

To evaluate the therapeutic effectiveness of intravenous bretylium tosylate as a first-line drug for patients in cardiopulmonary arrest, a randomized, double-blind study was conducted, comparing bretylium with a normal saline placebo. Fifty-nine patients presenting to the emergency department with cardiopulmonary arrest due mainly to ventricular fibrillation or asystole initially received either bretylium (10 mg/kg) or placebo in a rapid intravenous bolus and were then otherwise treated according to standard American Heart Association guidelines. If ventricular fibrillation or asystole persisted, a second bolus of bretylium or normal saline was given after 20 minutes. Thirty-five percent of patients presenting with ventricular fibrillation or asystole who received bretylium were successfully resuscitated, whereas 6% of patients who received placebo survived (P less than 0.05). These findings serve to suggest that the early use of bretylium tosylate in cardiopulmonary arrest improves survival.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP61756	Bretylium tosylate		61-75-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: